High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
MA Shipp, D Neuberg, M Janicek… - Journal of clinical …, 1995 - ascopubs.org
PURPOSE To purpose of this study was to develop a more effective approach to the
treatment of patients with poor-prognosis aggressive non-Hodgkin's lymphoma (NHL) …
treatment of patients with poor-prognosis aggressive non-Hodgkin's lymphoma (NHL) …
A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results
Background The value of continuous-infusion chemotherapy (EPOCH) vs. the standard
CHOP combination was evaluated in 78 patients with previously untreated aggressive non …
CHOP combination was evaluated in 78 patients with previously untreated aggressive non …
[HTML][HTML] Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG
A Olivieri, G Santini, C Patti, T Chisesi, C De Souza… - Annals of oncology, 2005 - Elsevier
Background: There is not univocal concordance for using high-dose sequential therapy
(HDS) as first-line treatment for aggressive non-Hodgkin's lymphoma (NHL). We designed …
(HDS) as first-line treatment for aggressive non-Hodgkin's lymphoma (NHL). We designed …
Limited stage aggressive non-hodgkin lymphoma: What is optimal therapy?
A Kumar, S Sundararajan, S Puvvada… - Current treatment options …, 2016 - Springer
Opinion Statement The seminal SWOG trial S8736 trial established the success of a short
course of chemotherapy followed by involved field radiation in treating limited stage …
course of chemotherapy followed by involved field radiation in treating limited stage …
Current treatment options in aggressive lymphoma
R Marcus - Leukemia & lymphoma, 2003 - Taylor & Francis
The overall percentage of patients achieving long-term remissions in aggressive non-
Hodgkin's lymphoma (NHL) using CHOP or CHOP-based primary chemotherapy is only …
Hodgkin's lymphoma (NHL) using CHOP or CHOP-based primary chemotherapy is only …
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell …
N Schmitz, M Nickelsen, M Ziepert, M Haenel… - The lancet …, 2012 - thelancet.com
Background High-dose therapy (HDT) followed by transplantation of autologous
haemopoietic stem cells is frequently done as part of first-line therapy in young patients with …
haemopoietic stem cells is frequently done as part of first-line therapy in young patients with …
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87–2 protocol—a groupe d'Etude des …
C Haioun, E Lepage, C Gisselbrecht… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: To present the final analysis, with a median follow-up of 8 years, of the LNH87–2
randomized study, which compares consolidative sequential chemotherapy (ifosfamide plus …
randomized study, which compares consolidative sequential chemotherapy (ifosfamide plus …
Aggressive lymphoma: improving treatment outcome with rituximab
B Coiffier, M Pfreundschuh, R Stahel, J Vose… - Anti-cancer …, 2002 - journals.lww.com
The standard therapy for patients with aggressive lymphoma is cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete …
doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete …
Dose-escalated CHOP plus etoposide (Hi-CHOEP) is not superior to base-line CHOEP in young good-prognosis patients with aggressive lymphoma: Results of a …
MG Pfreundschuh, S Zeynalova, U Duehrsen… - Journal of Clinical …, 2006 - ascopubs.org
7513 Background: The addition of etoposide to CHOP (CHOEP) resulted in improved
outcome of young patients with good-prognosis aggressive lymphoma (NHL-B1 trial; Blood …
outcome of young patients with good-prognosis aggressive lymphoma (NHL-B1 trial; Blood …